nach oben

Arthritis Research & Therapy

Erschienen in:

01.08.2013 | Review

Update on differences between childhood-onset and adult-onset systemic lupus erythematosus

verfasst von: Rina Mina, Hermine I Brunner

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease and occurs worldwide in both children and adults. The estimated annual incidence among children is 2.22/100,000 and among adults is 23.2/100,000 in the United States. There is increasing understanding about differences in disease manifestations, medication use, and disease severity between those with childhood-onset SLE as compared with adult-onset SLE. Children have a more fulminant disease onset and course than adults with SLE, resulting in two to three times higher mortality. In future years, we anticipate more insight into the genetics between childhood-onset SLE and adult-onset SLE to help delineate the best therapies for both subsets of patients.

Nur mit Berechtigung zugänglich

Hochberg M C: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed

Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, et al: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64: 2677-2686. 10.1002/art.34473.PubMedCentralCrossRefPubMed

Ferraz MB, Goldenberg J, Hilario MO, Bastos WA, Oliveira SK, Azevedo EC, di Napoli D: Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology. Clin Exp Rheumatol. 1994, 12: 83-87.PubMed

Silva CA, Avcin T, Brunner HI: Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012, 64: 1787-1793. 10.1002/acr.21757.CrossRef

Tiffin N, Adeyemo A, Okpechi I: A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J Rare Dis. 2013, 8: 2-10.1186/1750-1172-8-2.PubMedCentralCrossRefPubMed

Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, Winkelmayer WC, Costenbader KH: Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among U.S. adults with medicaid coverage, 2000-2004. Arthritis Rheum. 2013, 65: 753-763.PubMedCentralCrossRefPubMed

MEDICAID. [http://medicaid.gov]

Tsokos GC: Systemic lupus erythematosus. N Engl J Med. 2011, 365: 2110-2121. 10.1056/NEJMra1100359.CrossRefPubMed

Webb R, Kelly JA, Somers EC, Hughes T, Kaufman KM, Sanchez E, Nath SK, Bruner G, Alarcon-Riquelme ME, Gilkeson GS, Kamen DL, Richardson BC, Harley JB, Sawalha AH: Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2010, 70: 151-156.PubMedCentralCrossRefPubMed

10.

Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK: Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 2008, 58: 2113-2119. 10.1002/art.23619.PubMedCentralCrossRefPubMed

11.

Lashine YA, Seoudi AM, Salah S, Abdelaziz AI: Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2011, 29: 351-357.PubMed

12.

Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60: 1065-1075. 10.1002/art.24436.CrossRefPubMed

13.

Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC: Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology. 2012, 17: 346-351. 10.1111/j.1440-1797.2012.01573.x.CrossRefPubMed

14.

Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Nocton JJ, Solomon A, Zidovetzki R: Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 2007, 56: 4164-4173. 10.1002/art.23060.CrossRefPubMed

15.

Armstrong DL, Reiff A, Myones BL, Quismorio FP, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ojwang JO, Kaufman KM, Kelly JA, Merrill JT, Harley JB, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Putterman C, Edberg JC, Brown EE, Ziegler J, Langefeld CD, Zidovetzki R, Jacob CO: Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 2009, 10: 446-456. 10.1038/gene.2009.38.PubMedCentralCrossRefPubMed

16.

Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Katz P, Criswell LA, Yelin E: Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 13-20.PubMedCentralCrossRefPubMed

17.

Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED: Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008, 152: 550-556. 10.1016/j.jpeds.2007.09.019.CrossRefPubMed

18.

Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008, 58: 556-562. 10.1002/art.23204.CrossRefPubMed

19.

Zappitelli M, Duffy CM, Bernard C, Gupta IR: Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol. 2008, 23: 83-91.CrossRefPubMed

20.

Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC: Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus. 2007, 16: 28-34. 10.1177/0961203306074469.CrossRefPubMed

21.

Sato VA, Marques ID, Goldenstein PT, Carmo LP, Jorge LB, Titan SM, Barros RT, Woronik V: Lupus nephritis is more severe in children and adolescents than in older adults. Lupus. 2012, 21: 978-983. 10.1177/0961203312443421.CrossRefPubMed

22.

Hui-Yuen JS, Imundo LF, Avitabile C, Kahn PJ, Eichenfield AH, Levy DM: Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus. 2011, 20: 952-959. 10.1177/0961203311403022.CrossRefPubMed

23.

Descloux E, Durieu I, Cochat P, Vital-Durand D, Ninet J, Fabien N, Cimaz R: Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford). 2009, 48: 779-784. 10.1093/rheumatology/kep067.CrossRef

24.

Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, Dehoorne J, Joos R, Hendrickx G, Houssiau F, Elewaut D: Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009, 68: 412-415. 10.1136/ard.2008.094813.CrossRefPubMed

25.

Ramirez Gomez LA, Uribe Uribe O, Osio Uribe O, Grisales Romero H, Cardiel MH, Wojdyla D, Pons-Estel BA, Catoggio LJ, Soriano ER, Imamura PM, Manni JA, Grimaudo S, Sarano J, Maldonado-Cocco JA, Arriola MS, Gomez G, Garcia MA, Marcos AI, Marcos JC, Scherbarth HR, Marino PC, Motta EL, Drenkard C, Gamron S, Buliubasich S, Onetti CM, Caeiro F, Alvarellos A, Saurit V, Gentiletti S, et al: Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus. 2008, 17: 596-604. 10.1177/0961203307088006.CrossRefPubMed

26.

Livingston B, Bonner A, Pope J: Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011, 20: 1345-1355. 10.1177/0961203311416694.CrossRefPubMed

27.

Livingston B, Bonner A, Pope J: Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2012, 42: 271-280. 10.1016/j.semarthrit.2012.05.001.CrossRefPubMed

28.

Benseler SM, Silverman ED: Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007, 16: 564-571. 10.1177/0961203307078971.CrossRefPubMed

29.

Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, et al: Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007, 56: 265-273. 10.1002/art.22305.CrossRefPubMed

30.

Williams TS, Aranow C, Ross GS, Barsdorf A, Imundo LF, Eichenfield AH, Kahn PJ, Diamond B, Levy DM: Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis. Arthritis Care Res (Hoboken). 2011, 63: 1178-1187. 10.1002/acr.20489.CrossRef

31.

Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Hudson M, Tucker L, Peschken C: Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum. 2012, 42: 179-185. 10.1016/j.semarthrit.2012.03.011.CrossRefPubMed

32.

Muscal E, Brey RL: Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010, 28: 61-73. 10.1016/j.ncl.2009.09.004.PubMedCentralCrossRefPubMed

33.

Lilleby V: Bone status in juvenile systemic lupus erythematosus. Lupus. 2007, 16: 580-586. 10.1177/0961203307079040.CrossRefPubMed

34.

Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I, Chow SK, Goh EM: A comparison of calcium, calcitriol, and alendronate in corticosteroidtreated premenopausal patients with systemic lupus erythematosus. J Rheumatol. 2008, 35: 2344-2347. 10.3899/jrheum.080634.CrossRefPubMed

35.

Baker-LePain JC, Nakamura MC, Shepherd J, von Scheven E: Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford). 2011, 50: 611-619. 10.1093/rheumatology/keq307.CrossRef

36.

Wright TB, SJ , Leonard MB, Zemel BS, Burnham JM: Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr. 2009, 155: 260-265. 10.1016/j.jpeds.2009.02.033.CrossRefPubMed

37.

Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH: Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2011, 21: 36-42.CrossRefPubMed

38.

Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE: Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr. 2011, 160: 297-302.PubMedCentralCrossRefPubMed

39.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD: Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2011, 64: 285-296.CrossRef

40.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Levy DM, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A: Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum. 2009, 60: 1496-1507. 10.1002/art.24469.PubMedCentralCrossRefPubMed

41.

Lionaki S, Kapitsinou PP, Iniotaki A, Kostakis A, Moutsopoulos HM, Boletis JN: Kidney transplantation in lupus patients: a case-control study from a single centre. Lupus. 2008, 17: 670-675. 10.1177/0961203308089430.CrossRefPubMed

42.

Cochat P, Fargue S, Mestrallet G, Jungraithmayr T, Koch-Nogueira P, Ranchin B, Zimmerhackl LB: Disease recurrence in paediatric renal transplantation. Pediatr Nephrol. 2009, 24: 2097-2108. 10.1007/s00467-009-1137-6.PubMedCentralCrossRefPubMed

43.

Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcon GS, Solomon DH, Winkelmayer WC, Costenbader KH: End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011, 63: 1988-1997. 10.1002/art.30350.PubMedCentralCrossRefPubMed

44.

Chambers SA, Allen E, Rahman A, Isenberg D: Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009, 48: 673-675. 10.1093/rheumatology/kep062.CrossRef

45.

Huang JL, Yeh KW, Yao TC, Huang YL, Chung HT, Ou LS, Lee WI, Chen LC: Pediatric lupus in Asia. Lupus. 2010, 19: 1414-1418. 10.1177/0961203310374339.CrossRefPubMed

46.

Vachvanic hsanong P, Dissaneewate P, McNeil E: Twenty-two years' experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries?. Arch Dis Child. 2011, 96: 44-49. 10.1136/adc.2010.183699.CrossRef

47.

Petri M, Purvey S, Fang H, Magder LS: Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012, 64: 4021-4028. 10.1002/art.34672.PubMedCentralCrossRefPubMed

48.

Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM: Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002, 46: 436-444. 10.1002/art.10072.CrossRefPubMed

49.

Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcon GS: Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008, 17: 314-322. 10.1177/0961203307087875.PubMedCentralCrossRefPubMed

50.

Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, Criswell LA, Yelin E: Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62: 1152-1159. 10.1002/acr.20179.CrossRef

51.

Mina RK-GM, Nelson S, Eberhard BA, Higgins G, Singer NG, Onel K, Tucker L, O'Neil KM, Punaro M, Levy DM, Haines K, Martini A, Ruperto N, Lovell D, Brunner HI: Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis. 2013

52.

Mina R, Klein-Gitelman MS, Ravelli A, Beresford MW, Avcin T, Espada G, Eberhard BA, Schanberg LE, O'Neil KM, Silva CA, Higgins GC, Onel K, Singer NG, von Scheven E, Imundo LF, Nelson S, Giannini EH, Brunner HI: Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012, 64: 683-693. 10.1002/acr.21612.CrossRef

53.

Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner MI, Cronin ME, Dooley MA, Filocamo G, Fiorentino D, Fortin PR, Franks AG, Gilkeson G, Ginzler E, Gordon C, Grossman J, Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L, Sanchez-Guerrero J, Sontheimer RD, Strand V, Urowitz M, von Feldt JM, Werth VP, Merrill JT: International consensus for a definition of disease flare in lupus. Lupus. 2010, 20: 453-462.CrossRefPubMed

54.

Brunner HI, Klein-Gitelman MS, Higgins GC, Lapidus SK, Levy DM, Eberhard A, Singer N, Olson JC, Onel K, Punaro M, Schanberg L, von Scheven E, Ying J, Giannini EH: Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62: 811-820. 10.1002/acr.20126.CrossRef

55.

Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chedeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, et al: Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011, 64: 375-383.CrossRef

56.

Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006, 54: 421-432.CrossRef

57.

Watson L, Midgley A, Pilkington C, Tullus K, Marks S, Holt R, Jones C, Beresford M: Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus. 2011, 21: 496-501.CrossRefPubMed

58.

RRubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Reigosa JM, Lu TY, Isenberg D, Rahman A, Putterman C: Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford). 2010, 49: 960-971. 10.1093/rheumatology/kep468.CrossRef

59.

Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onel K, O'Neil K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI: Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009, 60: 2772-2781. 10.1002/art.24751.PubMedCentralCrossRefPubMed

60.

Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM, Manzi S: Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 837-844. 10.1002/art.27267.PubMedCentralCrossRefPubMed

61.

Reyes-Thomas J, Blanco I, Putterman C: Urinary bi omarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011, 40: 138-150. 10.1007/s12016-010-8197-z.PubMedCentralCrossRefPubMed

62.

Hollander MC, Sage JM, Greenler AJ, Pendl J, Avcin T, Espada G, Beresford MW, Henrickson M, Lee TL, Punaro M, Huggins J, Stevens AM, Klein-Gitelman MS, Brunner HI: International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013

63.

Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E: A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 370-377. 10.1002/art.24356.PubMedCentralCrossRefPubMed

64.

Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010, 69: 1269-1274. 10.1136/ard.2009.117200.PubMedCentralCrossRefPubMed

65.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez- Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63: 3918-3930. 10.1002/art.30613.CrossRefPubMed

66.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 1168-1178. 10.1002/art.24699.PubMedCentralCrossRefPubMed

67.

Kumar S, Benseler SM, Kirby-Allen M, Silverman ED: B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics. 2009, 123: e159-e163. 10.1542/peds.2008-2361.CrossRefPubMed

68.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harle JR, Hot A, Kahn JE, Lambotte O, Larroche C, Leone J, Meyer O, Pallot- Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, et al: Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010, 62: 2458-2466. 10.1002/art.27541.CrossRefPubMed

69.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62: 222-233. 10.1002/art.27233.PubMedCentralCrossRefPubMed

70.

Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012, 64: 797-808. 10.1002/acr.21664.CrossRef

71.

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, et al: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012, 71: 1771-1782. 10.1136/annrheumdis-2012-201940.PubMedCentralCrossRefPubMed

72.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353: 2219-2228. 10.1056/NEJMoa043731.CrossRefPubMed

73.

Sundel R, Solomons N, Lisk L: Efficacy of mycophe nolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012, 21: 1433-1443. 10.1177/0961203312458466.CrossRefPubMed

74.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011, 365: 1886-1895. 10.1056/NEJMoa1014460.CrossRefPubMed

75.

Henderson L, Masson P, Craig JC, Flanc RS, Robert s MA, Strippoli GF, Webster AC: Treatment for lupus nephritis. Cochrane Database Syst Rev. 2012, 12: CD002922-PubMed

76.

Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Gos s TF: A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken). 2011, 63: 1224-1232. 10.1002/acr.20502.CrossRef

77.

Tanzer M, Tran C, Messer KL, Kroeker A, Herreshoff E, Wickman L, Harkness C, Song P, Gipson DS: Inpatient healthcare utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care Res (Hoboken). 2013, 65: 382-390. 10.1002/acr.21815.CrossRef

78.

Zhu TY, Tam LS, Li EK: Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2011, 63: 751-760. 10.1002/acr.20410.CrossRef

Titel: Update on differences between childhood-onset and adult-onset systemic lupus erythematosus
verfasst von: Rina Mina
Hermine I Brunner
Publikationsdatum: 01.08.2013
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 4/2013
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar4256

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update on differences between childhood-onset and adult-onset systemic lupus erythematosus

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis

Correction: Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway

Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome

Clinical associations of serum interleukin-17 in systemic lupus erythematosus

Natriuretic peptide receptors regulate cytoprotective effects in a human ex vivo 3D/bioreactor model

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin